1. Home
  2. SVCO vs EDIT Comparison

SVCO vs EDIT Comparison

Compare SVCO & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SVCO
  • EDIT
  • Stock Information
  • Founded
  • SVCO 1984
  • EDIT 2013
  • Country
  • SVCO United States
  • EDIT United States
  • Employees
  • SVCO N/A
  • EDIT N/A
  • Industry
  • SVCO
  • EDIT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SVCO
  • EDIT Health Care
  • Exchange
  • SVCO NYSE
  • EDIT Nasdaq
  • Market Cap
  • SVCO 406.2M
  • EDIT 384.9M
  • IPO Year
  • SVCO 2024
  • EDIT 2016
  • Fundamental
  • Price
  • SVCO $14.99
  • EDIT $3.83
  • Analyst Decision
  • SVCO Strong Buy
  • EDIT Buy
  • Analyst Count
  • SVCO 6
  • EDIT 11
  • Target Price
  • SVCO $25.83
  • EDIT $11.50
  • AVG Volume (30 Days)
  • SVCO 355.8K
  • EDIT 1.5M
  • Earning Date
  • SVCO 08-07-2024
  • EDIT 11-01-2024
  • Dividend Yield
  • SVCO N/A
  • EDIT N/A
  • EPS Growth
  • SVCO N/A
  • EDIT N/A
  • EPS
  • SVCO N/A
  • EDIT N/A
  • Revenue
  • SVCO $58,279,000.00
  • EDIT $67,034,000.00
  • Revenue This Year
  • SVCO $21.35
  • EDIT N/A
  • Revenue Next Year
  • SVCO $20.35
  • EDIT N/A
  • P/E Ratio
  • SVCO N/A
  • EDIT N/A
  • Revenue Growth
  • SVCO 20.50
  • EDIT 247.04
  • 52 Week Low
  • SVCO $13.99
  • EDIT $3.40
  • 52 Week High
  • SVCO $21.59
  • EDIT $11.69
  • Technical
  • Relative Strength Index (RSI)
  • SVCO N/A
  • EDIT 49.01
  • Support Level
  • SVCO N/A
  • EDIT $3.45
  • Resistance Level
  • SVCO N/A
  • EDIT $3.97
  • Average True Range (ATR)
  • SVCO 0.00
  • EDIT 0.18
  • MACD
  • SVCO 0.00
  • EDIT 0.08
  • Stochastic Oscillator
  • SVCO 0.00
  • EDIT 92.98

About SVCO SILVACO GROUP INC

Silvaco Group Inc is a provider of technology computer aided design ("TCAD") software, electronic data automation ("EDA") software and semiconductor intellectual property ("SIP"). TCAD, EDA and SIP solutions enable semiconductor and photonics companies to increase productivity, accelerate their products' time-to-market and reduce their development and manufacturing costs. It is developing the "technology behind the chip" and providing solutions that span from atoms to systems, starting with providing software for the atomic level simulation of semiconductor and photonics material for devices, to providing software and SIP for the design and analysis of circuits and system level solutions.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: